United-Guardian Inc. Common Stock (UG) fair value

ACCE thesis

United-Guardian makes specialty ingredients for personal care and pharmaceutical formulators, most notably Lubrajel, a moisturizing polymer, and Renacidin, a urinary stone remover sold to physicians. The business runs at a 46.9% gross margin and a 24.3% operating margin, and an ROE of 21.3% on a $31M market cap is unusual for a company this small. Revenue growth of 9.5% is respectable, and the stock trades at 12.7 times trailing earnings, though the forward multiple of 26.5 suggests analysts expect earnings to fall back, so the cheapness on trailing numbers needs checking. At this size the name has no index membership and little coverage, which is why it can sit at a low trailing multiple while the business earns high returns. The first question for a deeper look is whether the forward earnings decline is real or a one-off, and whether the Renacidin franchise can keep growing.